Response to NGR-hTNF/RCHOP, consolidation, relapse, and survival
| Response to NGR-hTNF/R-CHOP . | Consolidation . | Response to consolidation . | Treatment failure . | TTTF, mo* . | Status . | Survival, mo* . |
|---|---|---|---|---|---|---|
| PD | None | — | Yes | 4 | DoD | 5 |
| CR | Lenalidomide | CR | Yes | 11 | DoD | 11 |
| PD | None | — | Yes | 4 | DoD | 14 |
| CR | WBRT > lenalidomide | CR | Yes | 6 | DoD | 18 |
| PD | None | — | Yes | 4 | DoD | 6 |
| CR | WBRT > lenalidomide | CR | Yes | 9 | DoD | 22 |
| CR | ASCT > WBRT | CR | Yes | 6 | Alive | 31 |
| CR | ASCT > lenalidomide | CR | Yes | 17 | Alive | 30 |
| CR | ASCT | CR | Yes | 9 | DoD | 11 |
| PR | WBRT | CR | No | 10 | DUC | 10 |
| CR | ASCT | CR | Yes | 6 | DoD | 7 |
| CR | ASCT | CR | No | 25 | Alive | 25 |
| PD | None | — | Yes | 1 | DoD | 2 |
| PD | None | — | Yes | 1 | DoD | 2 |
| CR | None | — | Yes | 13 | DoD | 19 |
| PR | WBRT | CR | Yes | 10 | DoD | 11 |
| PR | WBRT | PR | Yes | 5 | DoD | 7 |
| PR | WBRT | PR | Yes | 5 | DoD | 7 |
| PR | None | — | Yes | 5 | DoD | 6 |
| PD | None | — | Yes | 0 | DoD | 1 |
| PR | None | — | Yes | 5 | DoD | 7 |
| PR | None | — | Yes | 6 | DoD | 9 |
| PR | WBRT | PR | Yes | 7 | DoD | 8 |
| CR | ASCT | CR | No | 17 | Alive | 17 |
| PD | None | — | Yes | 1 | DoD | 3 |
| PR | WBRT | PR | Yes | 3 | DoD | 6 |
| CR | ASCT | CR | No | 14 | Alive | 14 |
| PR | WBRT | CR | No | 14 | Alive | 14 |
| Response to NGR-hTNF/R-CHOP . | Consolidation . | Response to consolidation . | Treatment failure . | TTTF, mo* . | Status . | Survival, mo* . |
|---|---|---|---|---|---|---|
| PD | None | — | Yes | 4 | DoD | 5 |
| CR | Lenalidomide | CR | Yes | 11 | DoD | 11 |
| PD | None | — | Yes | 4 | DoD | 14 |
| CR | WBRT > lenalidomide | CR | Yes | 6 | DoD | 18 |
| PD | None | — | Yes | 4 | DoD | 6 |
| CR | WBRT > lenalidomide | CR | Yes | 9 | DoD | 22 |
| CR | ASCT > WBRT | CR | Yes | 6 | Alive | 31 |
| CR | ASCT > lenalidomide | CR | Yes | 17 | Alive | 30 |
| CR | ASCT | CR | Yes | 9 | DoD | 11 |
| PR | WBRT | CR | No | 10 | DUC | 10 |
| CR | ASCT | CR | Yes | 6 | DoD | 7 |
| CR | ASCT | CR | No | 25 | Alive | 25 |
| PD | None | — | Yes | 1 | DoD | 2 |
| PD | None | — | Yes | 1 | DoD | 2 |
| CR | None | — | Yes | 13 | DoD | 19 |
| PR | WBRT | CR | Yes | 10 | DoD | 11 |
| PR | WBRT | PR | Yes | 5 | DoD | 7 |
| PR | WBRT | PR | Yes | 5 | DoD | 7 |
| PR | None | — | Yes | 5 | DoD | 6 |
| PD | None | — | Yes | 0 | DoD | 1 |
| PR | None | — | Yes | 5 | DoD | 7 |
| PR | None | — | Yes | 6 | DoD | 9 |
| PR | WBRT | PR | Yes | 7 | DoD | 8 |
| CR | ASCT | CR | No | 17 | Alive | 17 |
| PD | None | — | Yes | 1 | DoD | 3 |
| PR | WBRT | PR | Yes | 3 | DoD | 6 |
| CR | ASCT | CR | No | 14 | Alive | 14 |
| PR | WBRT | CR | No | 14 | Alive | 14 |
Patients are reported in the same order as in Table 2.
DoD, death [as a result] of disease; DUC, death [as a result of an] unknown cause.
TTTF, time to treatment failure and survival were estimated from trial registration.